What could they say to stop this downward spiral?
Earnings are not in the cards this year or next.
I don't totally disagree,but projecting sales for a drug in phase 1 or 2 testing is wishful thinking.
The more interesting fact today was the underwriters couldn't defend
The secondary price of 33.00. That tells me more than anything else
Not sure 3 billion. Just bought at 31. Underwriter could defend 33 or 32 or 31.
Doesn't look good,
does anyone know when the secondary will be priced?